A significantly higher percentage of patients with dry eye disease treated with OTX-101 experienced significant improvements in tear production and ocular surface integrity than patients treated with vehicle.
A randomized, multicenter, double-masked, vehicle-controlled phase 3 study included 744 patients with a history and clinical diagnosis of dry eye disease. Researchers evaluated the safety and efficacy of Cequa (OTX-101; cyclosporine ophthalmic solution 0.09%, Sun Pharmaceutical Industries) for the treatment of dry eye in 371 patients compared with 373 patients who received vehicle. The
Uncategorized